US$ 27.50
glp-1 drugs and lupus agents 'can help lower systemic inflammation,' show promise in rheumatology Can GLP-1 Medications Be Considered
Description
Bianchi M, DOria V, Braghini MR, Petrini S, Manco M

The drug class now includes multiple formulations from twice daily injections to once weekly options and even oral tablets providing flexibility for different patient needs and preferences

Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial Altimmune

Hypertension 67 , 10561063 (2016)

Research-context information only

Regul Pept 114: 189-196, 2003
